VRDN Q1 2017 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$2B

Q1 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$462,000-43.5% YoY

Gross Profit

-$4M-791.8% margin

Operating Income

-$7M-1501.9% margin

Net Income

-$7M-1510.8% margin

EPS (Diluted)

$-9.06

QoQ Revenue Growth

-38.9%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$419,000

Balance Sheet

Total Assets

$58M

Total Liabilities

$10M

Stockholders' Equity

$48M

Cash & Equivalents

$54M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$462,000	$818,000	-43.5%
Gross Profit	-$4M	$189,000	-2035.4%
Operating Income	-$7M	-$3M	-153.7%
Net Income	-$7M	-$3M	-153.1%